Does the media favor TBPH or NERV?

In the previous week, Minerva Neurosciences had 2 more articles in the media than Theravance Biopharma. MarketBeat recorded 3 mentions for Minerva Neurosciences and 1 mentions for Theravance Biopharma. Minerva Neurosciences' average media sentiment score of 0.20 beat Theravance Biopharma's score of 0.00 indicating that Minerva Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Theravance Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Minerva Neurosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AMPH or NERV?

In the previous week, Amphastar Pharmaceuticals had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 4 mentions for Amphastar Pharmaceuticals and 3 mentions for Minerva Neurosciences. Amphastar Pharmaceuticals' average media sentiment score of 0.76 beat Minerva Neurosciences' score of 0.20 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Minerva Neurosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, NERV or SGP?

Spyglass Pharma is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Minerva Neurosciences N/A N/A -$293.42M -$28.87 N/A Spyglass Pharma N/A N/A -$39.87M -$7.00 N/A

Is NERV or SGP more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Spyglass Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Minerva Neurosciences N/A N/A -31.72% Spyglass Pharma N/A -62.40% -24.83%

Which has stronger earnings & valuation, NERV or GLAS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Minerva Neurosciences N/A N/A -$293.42M -$28.87 N/A Glass House Brands N/A N/A N/A N/A N/A

Is NERV or GLAS more profitable?

Company Net Margins Return on Equity Return on Assets Minerva Neurosciences N/A N/A -31.72% Glass House Brands N/A N/A N/A

Minerva Neurosciences (NERV) Competitors

$4.84 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

NERV vs. TBPH, AMPH, SGP, ESPR, and GLAS

Should you buy Minerva Neurosciences stock or one of its competitors? Minerva Neurosciences's main competitors and comparable companies include Theravance Biopharma (TBPH), Amphastar Pharmaceuticals (AMPH), Spyglass Pharma (SGP), Esperion Therapeutics (ESPR), and Glass House Brands (GLAS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Minerva Neurosciences compare to Theravance Biopharma?

Theravance Biopharma (NASDAQ:TBPH) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Theravance Biopharma has a net margin of 51.58% compared to Minerva Neurosciences' net margin of 0.00%. Minerva Neurosciences' return on equity of 0.00% beat Theravance Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	51.58%	-0.77%	-0.46%
Minerva Neurosciences	N/A	N/A	-31.72%

In the previous week, Minerva Neurosciences had 2 more articles in the media than Theravance Biopharma. MarketBeat recorded 3 mentions for Minerva Neurosciences and 1 mentions for Theravance Biopharma. Minerva Neurosciences' average media sentiment score of 0.20 beat Theravance Biopharma's score of 0.00 indicating that Minerva Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Theravance Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Minerva Neurosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Theravance Biopharma has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.1, indicating that its stock price is 110% less volatile than the broader market.

Theravance Biopharma presently has a consensus target price of $19.40, suggesting a potential upside of 14.05%. Minerva Neurosciences has a consensus target price of $10.33, suggesting a potential upside of 113.50%. Given Minerva Neurosciences' higher probable upside, analysts plainly believe Minerva Neurosciences is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.25
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Theravance Biopharma has higher revenue and earnings than Minerva Neurosciences. Minerva Neurosciences is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$107.46M	8.22	$105.89M	$1.01	16.84
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A

99.1% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are owned by institutional investors. 7.7% of Theravance Biopharma shares are owned by insiders. Comparatively, 1.7% of Minerva Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Theravance Biopharma beats Minerva Neurosciences on 11 of the 16 factors compared between the two stocks.

How does Minerva Neurosciences compare to Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are held by insiders. Comparatively, 1.7% of Minerva Neurosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Amphastar Pharmaceuticals presently has a consensus target price of $22.50, indicating a potential upside of 4.17%. Minerva Neurosciences has a consensus target price of $10.33, indicating a potential upside of 113.50%. Given Minerva Neurosciences' higher probable upside, analysts plainly believe Minerva Neurosciences is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, Amphastar Pharmaceuticals had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 4 mentions for Amphastar Pharmaceuticals and 3 mentions for Minerva Neurosciences. Amphastar Pharmaceuticals' average media sentiment score of 0.76 beat Minerva Neurosciences' score of 0.20 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Minerva Neurosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amphastar Pharmaceuticals has a net margin of 10.76% compared to Minerva Neurosciences' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 14.98% beat Minerva Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%
Minerva Neurosciences	N/A	N/A	-31.72%

Amphastar Pharmaceuticals has higher revenue and earnings than Minerva Neurosciences. Minerva Neurosciences is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.28	$98.09M	$1.69	12.78
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A

Amphastar Pharmaceuticals has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.1, indicating that its share price is 110% less volatile than the broader market.

Summary

Amphastar Pharmaceuticals beats Minerva Neurosciences on 12 of the 14 factors compared between the two stocks.

How does Minerva Neurosciences compare to Spyglass Pharma?

Minerva Neurosciences (NASDAQ:NERV) and Spyglass Pharma (NASDAQ:SGP) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

34.6% of Minerva Neurosciences shares are owned by institutional investors. 1.7% of Minerva Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Minerva Neurosciences had 3 more articles in the media than Spyglass Pharma. MarketBeat recorded 3 mentions for Minerva Neurosciences and 0 mentions for Spyglass Pharma. Minerva Neurosciences' average media sentiment score of 0.20 beat Spyglass Pharma's score of 0.00 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Minerva Neurosciences	Neutral
Spyglass Pharma	Neutral

Minerva Neurosciences' return on equity of 0.00% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-31.72%
Spyglass Pharma	N/A	-62.40%	-24.83%

Spyglass Pharma is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A

Minerva Neurosciences presently has a consensus price target of $10.33, suggesting a potential upside of 113.50%. Spyglass Pharma has a consensus price target of $44.00, suggesting a potential upside of 65.98%. Given Minerva Neurosciences' higher probable upside, equities research analysts clearly believe Minerva Neurosciences is more favorable than Spyglass Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Minerva Neurosciences beats Spyglass Pharma on 7 of the 12 factors compared between the two stocks.

How does Minerva Neurosciences compare to Esperion Therapeutics?

Minerva Neurosciences (NASDAQ:NERV) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Esperion Therapeutics has higher revenue and earnings than Minerva Neurosciences. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A
Esperion Therapeutics	$403.14M	2.03	-$22.68M	-$0.06	N/A

In the previous week, Minerva Neurosciences had 3 more articles in the media than Esperion Therapeutics. MarketBeat recorded 3 mentions for Minerva Neurosciences and 0 mentions for Esperion Therapeutics. Minerva Neurosciences' average media sentiment score of 0.20 beat Esperion Therapeutics' score of 0.00 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Minerva Neurosciences	Neutral
Esperion Therapeutics	Neutral

34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 1.7% of Minerva Neurosciences shares are held by company insiders. Comparatively, 1.6% of Esperion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Esperion Therapeutics has a net margin of 0.12% compared to Minerva Neurosciences' net margin of 0.00%. Minerva Neurosciences' return on equity of 0.00% beat Esperion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-31.72%
Esperion Therapeutics	0.12%	-0.14%	0.12%

Minerva Neurosciences presently has a consensus target price of $10.33, suggesting a potential upside of 113.50%. Esperion Therapeutics has a consensus target price of $5.54, suggesting a potential upside of 74.21%. Given Minerva Neurosciences' higher probable upside, research analysts plainly believe Minerva Neurosciences is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Minerva Neurosciences has a beta of -0.1, suggesting that its stock price is 110% less volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

Summary

Esperion Therapeutics beats Minerva Neurosciences on 8 of the 14 factors compared between the two stocks.

How does Minerva Neurosciences compare to Glass House Brands?

Minerva Neurosciences (NASDAQ:NERV) and Glass House Brands (NYSE:GLAS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

Minerva Neurosciences currently has a consensus price target of $10.33, indicating a potential upside of 113.50%. Glass House Brands has a consensus price target of $16.00, indicating a potential upside of 62.44%. Given Minerva Neurosciences' higher possible upside, analysts plainly believe Minerva Neurosciences is more favorable than Glass House Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Glass House Brands	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-31.72%
Glass House Brands	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A
Glass House Brands	N/A	N/A	N/A	N/A	N/A

34.6% of Minerva Neurosciences shares are held by institutional investors. 1.7% of Minerva Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Minerva Neurosciences had 2 more articles in the media than Glass House Brands. MarketBeat recorded 3 mentions for Minerva Neurosciences and 1 mentions for Glass House Brands. Minerva Neurosciences' average media sentiment score of 0.20 beat Glass House Brands' score of -2.00 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Minerva Neurosciences	Neutral
Glass House Brands	Very Negative

Summary

Minerva Neurosciences beats Glass House Brands on 5 of the 7 factors compared between the two stocks.

Get Minerva Neurosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NERV vs. The Competition

Export

Metric	Minerva Neurosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$231.11M	$12.49B	$7.32B	$12.82B
Dividend Yield	N/A	2.62%	2.54%	10.78%
P/E Ratio	-0.17	789.80	272.90	24.25
Price / Sales	N/A	795.77	632.64	97.63
Price / Cash	N/A	15.47	29.03	36.90
Price / Book	-1.49	10.48	11.25	6.42
Net Income	-$293.42M	$2.81B	$3.47B	$348.89M
7 Day Performance	9.50%	2.63%	2.33%	0.57%
1 Month Performance	19.80%	5.22%	7.72%	4.90%
1 Year Performance	99.18%	7.34%	25.22%	17.06%

Minerva Neurosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
NERV Minerva Neurosciences	1.7112 of 5 stars	$4.84 flat	$10.33 +113.5%	+99.2%	$231.11M	N/A	N/A	9
TBPH Theravance Biopharma	2.1419 of 5 stars	$16.92 +0.1%	$19.40 +14.7%	+22.3%	$871.76M	$107.46M	16.75	110
AMPH Amphastar Pharmaceuticals	2.036 of 5 stars	$20.42 +0.5%	$22.00 +7.7%	-29.2%	$863.95M	$719.89M	12.08	1,976
SGP Spyglass Pharma	1.601 of 5 stars	$24.85 -1.2%	$45.00 +81.1%	N/A	$841.18M	N/A	N/A	65
ESPR Esperion Therapeutics	N/A	$3.18 flat	$5.54 +74.2%	N/A	$819.45M	$403.14M	N/A	200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NERV) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Minerva Neurosciences (NERV) Competitors

NERV vs. TBPH, AMPH, SGP, ESPR, and GLAS

How does Minerva Neurosciences compare to Theravance Biopharma?

Summary

How does Minerva Neurosciences compare to Amphastar Pharmaceuticals?

Summary

How does Minerva Neurosciences compare to Spyglass Pharma?

Summary

How does Minerva Neurosciences compare to Esperion Therapeutics?

Summary

How does Minerva Neurosciences compare to Glass House Brands?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV vs. The Competition

Minerva Neurosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Minerva Neurosciences (NERV) Competitors

NERV vs. TBPH, AMPH, SGP, ESPR, and GLAS

How does Minerva Neurosciences compare to Theravance Biopharma?

Is TBPH or NERV more profitable?

Does the media favor TBPH or NERV?

Which has more volatility and risk, TBPH or NERV?

Do analysts prefer TBPH or NERV?

Which has higher earnings and valuation, TBPH or NERV?

Do institutionals and insiders hold more shares of TBPH or NERV?

Summary

How does Minerva Neurosciences compare to Amphastar Pharmaceuticals?

Do insiders & institutionals have more ownership in AMPH or NERV?

Do analysts prefer AMPH or NERV?

Does the media refer more to AMPH or NERV?

Is AMPH or NERV more profitable?

Which has stronger valuation & earnings, AMPH or NERV?

Which has more volatility & risk, AMPH or NERV?

Summary

How does Minerva Neurosciences compare to Spyglass Pharma?

Do insiders & institutionals have more ownership in NERV or SGP?

Does the media prefer NERV or SGP?

Is NERV or SGP more profitable?

Which has stronger valuation and earnings, NERV or SGP?

Do analysts recommend NERV or SGP?

Summary

How does Minerva Neurosciences compare to Esperion Therapeutics?

Which has higher earnings and valuation, NERV or ESPR?

Does the media prefer NERV or ESPR?

Do insiders & institutionals hold more shares of NERV or ESPR?

Is NERV or ESPR more profitable?

Do analysts rate NERV or ESPR?

Which has more risk & volatility, NERV or ESPR?

Summary

How does Minerva Neurosciences compare to Glass House Brands?

Do analysts prefer NERV or GLAS?

Is NERV or GLAS more profitable?

Which has stronger earnings & valuation, NERV or GLAS?

Do insiders & institutionals have more ownership in NERV or GLAS?

Does the media refer more to NERV or GLAS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV vs. The Competition

Minerva Neurosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools